% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kayser:128877,
      author       = {S. Kayser$^*$ and A. Benner$^*$ and C. Thiede and U.
                      Martens and J. Huber and P. Stadtherr and J. W. G. Janssen
                      and C. Röllig and M. J. Uppenkamp and T. Bochtler$^*$ and
                      U. Hegenbart and G. Ehninger and A. D. Ho and P. Dreger and
                      A. Krämer$^*$},
      title        = {{P}retransplant {NPM}1 {MRD} levels predict outcome after
                      allogeneic hematopoietic stem cell transplantation in
                      patients with acute myeloid leukemia.},
      journal      = {Blood cancer journal},
      volume       = {6},
      number       = {7},
      issn         = {2044-5385},
      address      = {London [u.a.]},
      publisher    = {Nature Publishing Group},
      reportid     = {DKFZ-2017-04890},
      pages        = {e449 -},
      year         = {2016},
      abstract     = {The objective was to evaluate the prognostic impact of
                      pre-transplant minimal residual disease (MRD) as determined
                      by real-time quantitative polymerase chain reaction in 67
                      adult NPM1-mutated acute myeloid leukemia patients receiving
                      allogeneic hematopoietic stem cell transplantation (HSCT).
                      Twenty-eight of the 67 patients had a FLT3-ITD $(42\%).$
                      Median age at transplantation was 54.7 years, median
                      follow-up for survival from time of allografting was 4.9
                      years. At transplantation, 31 patients were in first, 20 in
                      second complete remission (CR) and 16 had refractory disease
                      (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR
                      patients. Overall survival (OS) for patients transplanted in
                      CR was significantly longer as compared to patients with RD
                      (P=0.004), irrespective of whether the patients were
                      transplanted in first or second CR (P=0.74). There was a
                      highly significant difference in OS after allogeneic HSCT
                      between pre-transplant MRD-positive and MRD-negative
                      patients (estimated 5-year OS rates of 40 vs $89\%;$
                      P=0.007). Multivariable analyses on time to relapse and OS
                      revealed pre-transplant NPM1 MRD levels $>1\%$ as an
                      independent prognostic factor for poor survival after
                      allogeneic HSCT, whereas FLT3-ITD had no impact. Notably,
                      outcome of patients with pre-transplant NPM1 MRD positivity
                      $>1\%$ was as poor as that of patients transplanted with
                      RD.},
      cin          = {G330 / C060},
      ddc          = {610},
      cid          = {I:(DE-He78)G330-20160331 / I:(DE-He78)C060-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:27471865},
      pmc          = {pmc:PMC5030374},
      doi          = {10.1038/bcj.2016.46},
      url          = {https://inrepo02.dkfz.de/record/128877},
}